Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 9/20 | 1.00 |
| ▸ | CCR2 | P41597 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659847 | 0.94 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL2804629 | 0.94 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL659846 | 0.94 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL224917 | 0.93 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| Hydrochloric Acid SCHEMBL2457372 | 0.92 | ROCK2 (0.98) | ROCK2ROCK1CCR2 | |
| Hydrochloric Acid SCHEMBL1716387 | 0.92 | ROCK2 (0.98) | ROCK2ROCK1CCR2 | |
| Hydrochloric Acid SCHEMBL2457485 | 0.91 | ROCK2 (0.96) | ROCK2ROCK1CCR2 | |
| SCHEMBL1716696 | 0.91 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL1716120 | 0.90 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL3619861 | 0.90 | ROCK2 (1.00) | ROCK2ROCK1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4338751-B1 | COMBINATION OF SEPETAPROST AND NETARSUDIL FOR USE IN THE PROPHYLAXIS OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | SANTEN PHARMACEUTICAL CO LTD (JP) | 2025-09-03 | — | — | EP | disclosed |
| US-20250090544-A1 | ANTIPSYCHOTIC AND USE THEREOF | NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) | 2025-03-20 | — | — | US | disclosed |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2025-01-21 | — | — | US | disclosed |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION | 2024-09-05 | — | — | US | disclosed |
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-07-25 | — | — | US | disclosed |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2024-05-07 | — | — | US | disclosed |
| EP-4338751-A2 | MEDICAMENT COMPRISING COMBINATION OF SEPETAPROST AND RHO-ASSOCIATED COILED-COIL CONTAINING PROTEIN KINASE INHIBITOR | Santen Pharmaceutical Co., Ltd. (JP) | 2024-03-20 | — | — | EP | disclosed |
| US-11918581-B2 | Combination therapy comprising JAK pathway inhibitor and rock inhibitor | INCYTE CORPORATION (US) | 2024-03-05 | — | — | US | disclosed |
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4274578-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | Incyte Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20100041671-A1 | Methods for treating glaucoma | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-02-18 | — | — | US | disclosed |
| US-20090325958-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009158587-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2008022182-A1 | METHODS FOR PROMOTING COUPLING BETWEEN BONE FORMATION AND RESORPTION | THE UAB RESEARCH FOUNDATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7217722-B2 | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20060052367-A1 | Remedy for glaucoma comprising rho kinase inhibitor and beta-blocker | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20050245509-A1 | Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins | SANTEN PHARMACECUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1568382-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND &bgr;-BLOCKER | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-1541151-A1 | REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918581-B2 | Combination therapy comprising JAK pathway inhibitor and rock inhibitor | JAK1, ROCK1, JAK3 | ROCK2 4/4885ROCK1 2/4885CCR2 1137/4885 |
| US-12201602-B2 | Medicament comprising combination of sepetaprost and Rho-associated coiled-coil containing protein kinase inhibitor | CIT, ROCK1, ROCK2 | ROCK2 3/4885ROCK1 2/4885CCR2 4031/4885 |
| US-11974994-B2 | Agent for treating or preventing glaucoma including a sulfonamide compound and another drug | PTGIS, PTGIR, PTGS1 | ROCK2 539/4885ROCK1 725/4885CCR2 4770/4885 |
| US-20240245668-A1 | AGENT FOR TREATING OR PREVENTING GLAUCOMA INCLUDING A SULFONAMIDE COMPOUND AND ANOTHER DRUG | PTGIS, PTGIR, PTGS1 | ROCK2 539/4885ROCK1 725/4885CCR2 4770/4885 |
| US-20240293411-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | JAK1, ROCK1, JAK3 | ROCK2 4/4885ROCK1 2/4885CCR2 1137/4885 |
| US-20090325958-A1 | METHOD FOR TREATING PULMONARY DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK1, RHOA, ROCK2 | ROCK2 3/4885ROCK1 1/4885CCR2 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.